Literature DB >> 23750647

Genes, assisted reproductive technology and trans-illumination.

Renuka P Dias1, Eamonn R Maher.   

Abstract

Genomic imprinting is a parent-of-origin allele-specific epigenetic process that is critical for normal development and health. The establishment and maintenance of normal imprinting is dependent on both cis-acting imprinting control centers, which are marked by differentially (parental allele specific) methylated marks, and trans mechanisms, which regulate the establishment and/or maintenance of the correct methylation epigenotype at the imprinting control centers. Studies of rare human imprinting disorders such as familial hydatidiform mole, Beckwith-Wiedemann syndrome and familial transient neonatal diabetes mellitus have enabled the identification of genetic (e.g., mutations in KHDC3L [C6ORF221], NLRP2 [NALP2], NLRP7 [NALP7] and ZFP57) and environmental (assisted reproductive technologies) factors that can disturb the normal trans mechanisms for imprinting establishment and/or maintenance. Here we review the clinical and molecular aspects of these imprinting disorders in order to demonstrate how the study of rare inherited disorders can illuminate the molecular characteristics of fundamental epigenetic processes, such as genomic imprinting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23750647     DOI: 10.2217/epi.13.28

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  2 in total

1.  NLRP7 inter-domain interactions: the NACHT-associated domain is the physical mediator for oligomeric assembly.

Authors:  Heike Singer; Arijit Biswas; Nicole Zimmer; Christiane Messaed; Johannes Oldenburg; Rima Slim; Osman El-Maarri
Journal:  Mol Hum Reprod       Date:  2014-07-31       Impact factor: 4.025

2.  NLRP7, Involved in Hydatidiform Molar Pregnancy (HYDM1), Interacts with the Transcriptional Repressor ZBTB16.

Authors:  Heike Singer; Arijit Biswas; Nicole Nuesgen; Johannes Oldenburg; Osman El-Maarri
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.